ARTICLES IN THREE SENTENCES
Non-typhoidal Salmonella (NTS) bacteremia is highly prevalent in areas with concurrent malaria endemicity and the association between NTS and malaria has been particularly observed in children with severe malarial anemia (SMA). Abuga et al investigated the relationship between malaria, anemia and NTS in 75,034 children and then estimated levels of hepcidin in children with NTS bacteremia and malaria. SMA was associated with a strongly increased risk of NTS bacteremia and reduced hepcidin levels were observed in children with SMA and SMA+NTS; therefore, the authors hypothesized that reduced hepcidin might contribute to NTS growth by modulating iron availability for bacterial growth.
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
This multicenter phase I/II study evaluated combination therapy with temsirolimus and lenalidomide (TEM/LEN) in patients with relapsed/refractory lymphomas. The primary endpoints were rates of complete (CR) and overall response (ORR). ORR were 26% (13% CR) for the diffuse large B-cell lymphoma patients, and 80% (35% CR) for classical Hodgkin lymphoma (cHL) patients, most of whom had relapsed after both brentuximab vedotin and autologous stem cell transplantation. Combination therapy with TEM/LEN was feasible and demonstrated encouraging activity in heavily-pretreated lymphomas, particularly in relapsed/refractory cHL.
The pathogenic basis of primary cutaneous anaplastic large cell lymphoma (pcALCL), a hematologic neoplasm produced by malignant CD30+ large T cells that infiltrate the skin forming solitary or localized tumors, has remained elusive. Bastidas Torres et al performed high-resolution genetic profiling (genome/transcriptome) of pcALCL. They uncovered novel genetic alterations with pathogenic significance and established relevant molecular characteristics of pcALCL, which, indeed, appears to develop as a result of defects in genes with roles in the cell cycle, T-cell physiology, transcription, and especially signaling via the PI-3-K/AKT pathway, the MAPK pathway and G-proteins.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by chronic hemolysis mediated entirely by activation of the classical complement pathway. There are currently no approved therapies for CAD. Sutimlimab is a humanized monoclonal antibody designed to target C1s, the C1 complex serine protease responsible for activating the classical complement pathway which triggers hemolysis in CAD. Röth et al presented 1-year interim results of the ongoing 2-year CARDINAL extension which show that sutimlimab maintained mean hemoglobin levels ≥11 g/dL with sustained improvement in quality of life.
TAKE ADVANTAGE FROM HAEMATOLOGICA